Consequently, add-on drugs that target the resistance mechanisms, such as the PI3K inhibitor alpelisib and the mTOR inhibitor everolimus, have shown promising results in clinical trials for advanced ER+ breast cancers. Here, PIK3CA is linked to breast carcinoma.